^
Association details:
| Biomarker: | EGFR mutation + ALK mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OA06.06 - Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
Published date:
01/12/2021
Excerpt:
Patients received neoadjuvant atezolizumab 1200 mg intravenously every 3 weeks for ≤2 cycles followed by surgical resection...Data suggest MPR was positively associated with PD-L1 expression and negatively associated with EGFR/ALK alterations
Trial ID:
